[BARR LABORATORIES LOGO]

                                                                  Exhibit 99.0

2 Quaker Road                                          N E W S   R E L E A S E
Pomona, NY 10970
845-362-1100

CONTACT:    Carol A. Cox, 845-348-6808    EMAIL:    ccox@barrlabs.com

            BARR ANNOUNCES DISMISSAL OF TAMOXIFEN ANTITRUST LAWSUITS

Pomona, NY, May 15, 2003...Barr Laboratories, Inc. (NYSE-BRL) today announced
that the U.S. District Court for the Eastern District of New York has granted
its motion to dismiss in the In Re Tamoxifen Citrate Antitrust Litigation. In
the order, U.S. District Judge I. Leo Glasser dismissed the plaintiffs' claim
that the 1993 settlement agreement between Barr and AstraZeneca violated federal
antitrust statutes, as well as the antitrust and/or consumer protection statutes
of various states. Plaintiffs had argued that the settlement insulated Barr and
AstraZeneca from generic competition, and resulted in artificially inflated
Tamoxifen prices.

"Judge Glasser's decision vindicates our ability to settle patent challenge
cases," said Bruce L. Downey, Barr's Chairman and Chief Executive Officer. "This
particular settlement saved breast cancer patients millions of dollars that
would not have been available if we had not entered into this agreement."

In 1993, as a result of a patent challenge, Barr and AstraZeneca entered into an
agreement that resulted in the distribution by Barr of a more affordable version
of AstraZeneca's Nolvadex(R) treatment for breast cancer. That agreement expired
in August 2002. AstraZeneca's pediatric exclusivity, which prevented generic
competition, expired in February 2003. Barr launched its generic version of
Tamoxifen Citrate in February 2003. Approximately 30 putative class action
complaints were filed by consumers and/or third party payors in state and
federal courts against Barr and AstraZeneca. All complaints were consolidated in
the U.S. District Court for the Eastern District of New York. The order
dismissed both the state and federal claims. A prior investigation into this
agreement by the U.S. Department of Justice was closed without further action.

Barr Laboratories, Inc. is a specialty pharmaceutical company engaged in the
development, manufacture and marketing of generic and proprietary
pharmaceuticals.

SAFE HARBOR STATEMENT: TO THE EXTENT THAT ANY STATEMENTS MADE IN THIS REPORT
CONTAIN INFORMATION THAT IS NOT HISTORICAL, THESE STATEMENTS ARE ESSENTIALLY
FORWARD-LOOKING. THESE STATEMENTS ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT
CANNOT BE PREDICTED OR QUANTIFIED AND, CONSEQUENTLY, ACTUAL RESULTS MAY DIFFER
MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS.
SUCH RISKS AND UNCERTAINTIES INCLUDE: THE DIFFICULTY IN PREDICTING THE TIMING
AND OUTCOME OF LEGAL PROCEEDINGS, INCLUDING THOSE RELATING TO PATENT CHALLENGE
SETTLEMENTS AND PATENT INFRINGEMENT CASES; THE DIFFICULTY OF PREDICTING THE
TIMING OF U.S. FOOD AND DRUG ADMINISTRATION, OR FDA, APPROVALS; COURT AND FDA
DECISIONS ON EXCLUSIVITY PERIODS; THE ABILITY OF COMPETITORS TO EXTEND
EXCLUSIVITY PERIODS PAST INITIAL PATENT TERMS; MARKET AND CUSTOMER ACCEPTANCE
AND DEMAND FOR OUR PHARMACEUTICAL PRODUCTS; REIMBURSEMENT POLICIES OF THIRD
PARTY PAYORS; OUR ABILITY TO MARKET OUR PROPRIETARY PRODUCTS; THE SUCCESSFUL
INTEGRATION OF ACQUIRED BUSINESSES AND PRODUCTS INTO OUR OPERATIONS; THE USE OF
ESTIMATES IN THE PREPARATION OF OUR FINANCIAL STATEMENTS; THE IMPACT OF
COMPETITIVE PRODUCTS AND PRICING; THE ABILITY TO DEVELOP AND LAUNCH NEW PRODUCTS
ON A TIMELY BASIS; THE AVAILABILITY OF RAW MATERIALS; AVAILABILITY OF ANY
PRODUCT WE PURCHASE AND SELL AS A DISTRIBUTOR; THE REGULATORY ENVIRONMENT;
FLUCTUATIONS IN OPERATING RESULTS, INCLUDING SPENDING FOR RESEARCH AND
DEVELOPMENT, SALES AND MARKETING AND PATENT CHALLENGE ACTIVITIES; AND, OTHER
RISKS DETAILED FROM TIME-TO-TIME IN OUR FILINGS WITH THE SECURITIES AND EXCHANGE
COMMISSION, OR SEC. FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF
WORDS SUCH AS "EXPECTS," "PLANS," "WILL," "MAY," "ANTICIPATES," "BELIEVES,"
"SHOULD," "INTENDS," "ESTIMATES," AND OTHER WORDS OF SIMILAR MEANING. THESE
STATEMENTS ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT CANNOT BE PREDICTED OR
QUANTIFIED AND, CONSEQUENTLY, ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE
EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENT. THE COMPANY UNDERTAKES
NO OBLIGATION TO PUBLICLY UPDATE ANY FORWARD-LOOKING STATEMENTS.

[EDITOR'S ADVISORY: Barr Laboratories, Inc. news releases are available free
of charge through PR Newswire's News On-Call fax service. For a menu of
Barr's previous releases, or to receive a specific release via fax call:
800-758-5804 -- ext. 089750. Nolvadex is a registered trademark of AstraZeneca]

                                     # # #